000145046 001__ 145046
000145046 005__ 20250415092455.0
000145046 0247_ $$2doi$$a10.1002/mds.27964
000145046 0247_ $$2pmid$$apmid:31951049
000145046 0247_ $$2ISSN$$a0885-3185
000145046 0247_ $$2ISSN$$a1531-8257
000145046 0247_ $$2altmetric$$aaltmetric:74188526
000145046 037__ $$aDZNE-2020-00406
000145046 041__ $$aEnglish
000145046 082__ $$a610
000145046 1001_ $$0P:(DE-2719)9000949$$aPiot, Ines$$b0$$eFirst author$$udzne
000145046 245__ $$aThe Progressive Supranuclear Palsy Clinical Deficits Scale.
000145046 260__ $$aNew York, NY$$bWiley$$c2020
000145046 264_1 $$2Crossref$$3online$$bWiley$$c2020-01-17
000145046 264_1 $$2Crossref$$3print$$bWiley$$c2020-04-01
000145046 3367_ $$2DRIVER$$aarticle
000145046 3367_ $$2DataCite$$aOutput Types/Journal article
000145046 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744701853_3743
000145046 3367_ $$2BibTeX$$aARTICLE
000145046 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000145046 3367_ $$00$$2EndNote$$aJournal Article
000145046 520__ $$aThere is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.To develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.The Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).Cognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P < 0.001). Individual Progressive Supranuclear Palsy Clinical Deficits Scale items correlated well with similar constructs in existing scales. Internal consistency (Cronbach's alpha: 0.75), inter-rater reliability (0.96), and test-retest stability (0.99) were acceptable. The PSP-CDS showed significant 12-month change (baseline, 8.6 ± 3.6; follow-up: 10.8 ± 3.6; annualized difference: 3.4 ± 3.4; n = 49; P < 0.0001). Sample sizes required per arm for a two-arm, 1-year follow-up therapeutic trial to detect 50% change in Progressive Supranuclear Palsy Clinical Deficits Scale progression was estimated to be 65 (two-sided, two-sample t test).The Progressive Supranuclear Palsy Clinical Deficits Scale is a rapidly completed, clinimetrically sound scale for clinical care and research involving PSP. © 2020 International Parkinson and Movement Disorder Society.
000145046 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000145046 542__ $$2Crossref$$i2020-01-17$$uhttp://onlinelibrary.wiley.com/termsAndConditions#vor
000145046 542__ $$2Crossref$$i2020-01-17$$uhttp://doi.wiley.com/10.1002/tdm_license_1.1
000145046 588__ $$aDataset connected to CrossRef, PubMed,
000145046 650_2 $$2MeSH$$aDisease Progression
000145046 650_2 $$2MeSH$$aFemale
000145046 650_2 $$2MeSH$$aFingers
000145046 650_2 $$2MeSH$$aHumans
000145046 650_2 $$2MeSH$$aMale
000145046 650_2 $$2MeSH$$aMotor Skills
000145046 650_2 $$2MeSH$$aReproducibility of Results
000145046 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000145046 7001_ $$0P:(DE-2719)2811446$$aSchweyer, Kerstin$$b1$$udzne
000145046 7001_ $$0P:(DE-2719)2811600$$aRespondek, Gesine$$b2$$udzne
000145046 7001_ $$0P:(DE-HGF)0$$aStamelou, Maria$$b3
000145046 7001_ $$0P:(DE-HGF)0$$agroup, DescribePSP study$$b4$$eCollaboration Author
000145046 7001_ $$0P:(DE-HGF)0$$agroup, ProPSP study$$b5$$eCollaboration Author
000145046 7001_ $$0P:(DE-HGF)0$$agroup, MDS-endorsed PSP study$$b6$$eCollaboration Author
000145046 7001_ $$0P:(DE-HGF)0$$aSckopke, Philipp$$b7
000145046 7001_ $$0P:(DE-HGF)0$$aSchenk, Thomas$$b8
000145046 7001_ $$0P:(DE-HGF)0$$aGoetz, Christopher G$$b9
000145046 7001_ $$0P:(DE-HGF)0$$aStebbins, Glenn T$$b10
000145046 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b11$$eLast author$$udzne
000145046 7001_ $$0P:(DE-HGF)0$$aGasser, Thomas$$b12
000145046 7001_ $$0P:(DE-HGF)0$$aHermann, Andreas$$b13
000145046 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter$$b14
000145046 7001_ $$0P:(DE-HGF)0$$aHöllerhage, Matthias$$b15
000145046 7001_ $$0P:(DE-HGF)0$$aKimmich, Okka$$b16
000145046 7001_ $$0P:(DE-HGF)0$$aKlockgether, Thomas$$b17
000145046 7001_ $$0P:(DE-HGF)0$$aLevin, Johannes$$b18
000145046 7001_ $$0P:(DE-HGF)0$$aMachetanz, Gerrit$$b19
000145046 7001_ $$0P:(DE-HGF)0$$aOsterrath, Antje$$b20
000145046 7001_ $$0P:(DE-HGF)0$$aPalleis, Carla$$b21
000145046 7001_ $$0P:(DE-HGF)0$$aPrudlo, Johannes$$b22
000145046 7001_ $$0P:(DE-HGF)0$$aSpottke, Annika$$b23
000145046 7001_ $$0P:(DE-HGF)0$$aBerg, Daniela$$b24
000145046 7001_ $$aBürk, Katrin$$b25
000145046 7001_ $$aClaßen, Joseph$$b26
000145046 7001_ $$aEggers, Carsten$$b27
000145046 7001_ $$aGreuel, Andrea$$b28
000145046 7001_ $$0P:(DE-HGF)0$$aGrimm, Max-Joseph$$b29
000145046 7001_ $$aHermann, Lennard$$b30
000145046 7001_ $$aIankova, Vassilena$$b31
000145046 7001_ $$aJahn, Klaus$$b32
000145046 7001_ $$aJost, Wolfgang$$b33
000145046 7001_ $$aKlietz, Martin$$b34
000145046 7001_ $$0P:(DE-HGF)0$$aKühn, Andrea$$b35
000145046 7001_ $$aMarxreiter, Franz$$b36
000145046 7001_ $$aPaschen, Steffen$$b37
000145046 7001_ $$aPoetter-Nerger, Monika$$b38
000145046 7001_ $$aPreisl, Marie-Therese$$b39
000145046 7001_ $$aPrilop, Lisa$$b40
000145046 7001_ $$aTönges, Lars$$b41
000145046 7001_ $$aTrenkwalder, Claudia$$b42
000145046 7001_ $$aWarnecke, Tobias$$b43
000145046 7001_ $$aWegner, Florian$$b44
000145046 7001_ $$aWinkler, Jürgen$$b45
000145046 7001_ $$aAntonini, Angelo$$b46
000145046 7001_ $$aP, Kailash P$$b47
000145046 7001_ $$aL, Adam L$$b48
000145046 7001_ $$aColosimo, Carlo$$b49
000145046 7001_ $$aCompta, Yaroslau$$b50
000145046 7001_ $$aCorvol, Jean-Christophe$$b51
000145046 7001_ $$aI, Lawrence I$$b52
000145046 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter U$$b53
000145046 7001_ $$aE, Anthony E$$b54
000145046 7001_ $$aLitvan, Irene$$b55
000145046 7001_ $$aR, Huw R$$b56
000145046 7001_ $$aNilsson, Christer$$b57
000145046 7001_ $$aPantelyat, Alexander$$b58
000145046 7001_ $$0P:(DE-HGF)0$$aRespondek, Gesine$$b59
000145046 7001_ $$aStamelou, Maria$$b60
000145046 77318 $$2Crossref$$3journal-article$$a10.1002/mds.27964$$b : Wiley, 2020-01-17$$n4$$p650-661$$tMovement Disorders$$v35$$x0885-3185$$y2020
000145046 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.27964$$gVol. 35, no. 4, p. 650 - 661$$n4$$p650-661$$tMovement disorders$$v35$$x0885-3185$$y2020
000145046 8564_ $$uhttps://pub.dzne.de/record/145046/files/DZNE-2020-00406_Restricted.pdf
000145046 8564_ $$uhttps://pub.dzne.de/record/145046/files/DZNE-2020-00406_Restricted.pdf?subformat=pdfa$$xpdfa
000145046 909CO $$ooai:pub.dzne.de:145046$$pVDB
000145046 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000949$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000145046 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811446$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000145046 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811600$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000145046 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000145046 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000145046 9141_ $$y2020
000145046 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-02-26$$wger
000145046 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-26
000145046 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000145046 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000145046 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000145046 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x0
000145046 980__ $$ajournal
000145046 980__ $$aVDB
000145046 980__ $$aI:(DE-2719)1110002
000145046 980__ $$aUNRESTRICTED
000145046 999C5 $$2Crossref$$oRösler TW 2019$$y2019
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.26987$$o10.1002/mds.26987
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(17)30157-6$$o10.1016/S1474-4422(17)30157-6
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1749-6632.1998.tb11015.x$$o10.1111/j.1749-6632.1998.tb11015.x
000145046 999C5 $$2Crossref$$oEuropean Medicines Agency (EMA) The Netherlands: EMA 2016$$tThe Netherlands: EMA$$y2016
000145046 999C5 $$2Crossref$$o
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(07)60250-5$$o10.1016/S0140-6736(07)60250-5
000145046 999C5 $$2Crossref$$oCampbell M. Measuring How Patients Feel and Function 2017$$tMeasuring How Patients Feel and Function$$y2017
000145046 999C5 $$2Crossref$$oFahn S Elton RL; UPDRS Program Members. Recent Developments in Parkinson's Disease 1987$$tElton RL; UPDRS Program Members. Recent Developments in Parkinson's Disease$$y1987
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2288-6-26$$o10.1186/1471-2288-6-26
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/1531-8257(200003)15:2<276::AID-MDS1010>3.0.CO;2-Q$$o10.1002/1531-8257(200003)15:2<276::AID-MDS1010>3.0.CO;2-Q
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.55.11.1621$$o10.1212/WNL.55.11.1621
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mdc3.12130$$o10.1002/mdc3.12130
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1017/S1041610209008862$$o10.1017/S1041610209008862
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.26580$$o10.1002/mds.26580
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0074486$$o10.1371/journal.pone.0074486
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1532-5415.2005.53221.x$$o10.1111/j.1532-5415.2005.53221.x
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00702-016-1589-3$$o10.1007/s00702-016-1589-3
000145046 999C5 $$2Crossref$$oSchwab R England A. Projection technique for evaluating surgery in Parkinson's disease In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease 1969$$tEngland A. Projection technique for evaluating surgery in Parkinson's disease In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease$$y1969
000145046 999C5 $$2Crossref$$oGuy W ed. ECDEU assessment manual for psychopharmacology 1976$$ted. ECDEU assessment manual for psychopharmacology$$y1976
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2016.04.014$$o10.1016/j.parkreldis.2016.04.014
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/01.wnl.0000223826.84080.97$$o10.1212/01.wnl.0000223826.84080.97
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/awm032$$o10.1093/brain/awm032
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(14)70088-2$$o10.1016/S1474-4422(14)70088-2
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25824$$o10.1002/mds.25824
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.27034$$o10.1002/mds.27034
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s11524-011-9632-z$$o10.1007/s11524-011-9632-z
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1023/A:1023254226592$$o10.1023/A:1023254226592
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3233/JPD-130310$$o10.3233/JPD-130310
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.26054$$o10.1002/mds.26054
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/awh488$$o10.1093/brain/awh488
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/01.wnl.0000267643.24870.26$$o10.1212/01.wnl.0000267643.24870.26
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3988/jcn.2010.6.3.148$$o10.3988/jcn.2010.6.3.148
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/13554794.2011.627345$$o10.1080/13554794.2011.627345
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000068502$$o10.1159/000068502
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00401-003-0756-4$$o10.1007/s00401-003-0756-4
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/WCO.0b013e3283168ddd$$o10.1097/WCO.0b013e3283168ddd
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/awq123$$o10.1093/brain/awq123
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/archneur.58.2.259$$o10.1001/archneur.58.2.259
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1097/WAD.0b013e3182420bfe$$o10.1097/WAD.0b013e3182420bfe
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000323867$$o10.1159/000323867
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/awq158$$o10.1093/brain/awq158
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2217/nmt-2016-0027$$o10.2217/nmt-2016-0027
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/arclin/acs098$$o10.1093/arclin/acs098
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.5116/ijme.4dfb.8dfd$$o10.5116/ijme.4dfb.8dfd
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1037/pas0000626$$o10.1037/pas0000626
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jretconser.2010.06.003$$o10.1016/j.jretconser.2010.06.003
000145046 999C5 $$2Crossref$$oCicchetti DV 1981$$y1981
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1037/0033-2909.86.2.420$$o10.1037/0033-2909.86.2.420
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/bmj.322.7297.1297$$o10.1136/bmj.322.7297.1297
000145046 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jclinepi.2006.03.012$$o10.1016/j.jclinepi.2006.03.012